TNYA
NASDAQTenaya Therapeutics Inc.
News · 26 weeks43+200%
2026-03-012026-08-23
Mix2690d
- Insider11(42%)
- SEC Filings7(27%)
- Other5(19%)
- Earnings1(4%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.SCHEDULE 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)
- INSIDERChief Executive Officer Ali Faraz sold $15,778 worth of shares (22,232 units at $0.71), decreasing direct ownership by 5% to 417,782 units (SEC Form 4) to cover taxes4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERChief Medical Officer Tingley Whittemore sold $5,270 worth of shares (7,424 units at $0.71), decreasing direct ownership by 3% to 214,073 units (SEC Form 4) (withholding obligation)4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- SECSEC Form 144 filed by Tenaya Therapeutics Inc.144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
- SECSEC Form S-8 filed by Tenaya Therapeutics Inc.S-8 - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- SECSEC Form 10-Q filed by Tenaya Therapeutics Inc.10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- SECTenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- PRTenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatePositive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Trial Plans for TN-201 and TN-401 Anticipated in 4Q 2026 TN-301 Advancing toward Phase 2 Trial Start in 2H 2027 $10 million Upfront Payment Received from Alnylam Collaboration Extends Cash Runway Through Q3 2027 SOUTH SAN FRANCISCO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underly
- PRTenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth ConferenceSOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of management will host 1x1 meetings with investors at the upcoming Canaccord Genuity 46th Annual Growth Conference taking place from August 11-12, 2026 in Boston, Massachusetts. Eric Hyllengren, Tenaya’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 12:30 pm ET. The live webcast of the fireside chat may be accessed from the Investors section o
- INSIDERSEC Form 3 filed by new insider Hyllengren Eric J3 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Hyllengren Eric J4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- PRTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $0.8365 per share, which is equal to the closing price of Tenaya’s
- SECTenaya Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- SECTenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- PRTenaya Therapeutics Appoints Eric Hyllengren as Chief Financial OfficerSOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development. "We are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through a variety of strategic clinical and co
- PRTenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in SymptomsAll Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA's Rare Disease Evidence Principles Process Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported promising new interim safety and efficacy data from the company's MyPEAK™-1 Phase 1b/2 clinica
- PRTenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026. Webcast Details: Tenaya Therapeutics will host a live webcast to review the new data from MyPEAK™-1 on Wednesday, June 3, 2026 at 8:00 a.m. ET. To access the live event, participa
- INSIDERSEC Form 4 filed by Director Williams R Sanders4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Walsh Jeffrey T.4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Stehman-Breen Catherine4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Srivastava Deepak4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Parschauer Karah Herdman4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Lee June4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Burroughs Amy L.4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- SECTenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
TNYA FAQ
7 questionsWhat does Tenaya Therapeutics Inc. do?
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.Where does TNYA stock trade?
Tenaya Therapeutics Inc. (TNYA) is listed on NASDAQ.What sector and industry is TNYA in?
Tenaya Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tenaya Therapeutics Inc. go public?
Tenaya Therapeutics Inc. (TNYA) completed its IPO in 2021.What are analysts saying about TNYA?
Tenaya Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2024-06-10.What companies are similar to TNYA?
Notable peers in the same industry include ELYM (Eliem Therapeutics Inc), SGTX (Sigilon Therapeutics Inc.), TPST (Tempest Therapeutics Inc.). Compare TNYA side-by-side with any of them on Quantisnow.How can I track TNYA on Quantisnow?
Quantisnow aggregates Tenaya Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TNYA to receive live email and push alerts on every new disclosure.